01:58 AM EDT, 05/01/2026 (MT Newswires) -- Truist Securities expects Eli Lilly's (LLY.SW, LLY.F) incretin portfolio to support the US pharmaceutical giant's growth for the rest of 2026 and beyond.

"We remain Buyers of LLY following today's 1Q earnings that reinforced continued volume growth in Mounjaro and Zepbound and expanding margins, despite pricing headwinds, and improving global access. Mounjaro is the leading US diabetes incretin, Zepbound dominates obesity starts, and Foundayo is making inroads with ~20,000 patients on Foundayo to day having only been launched in early April. With additional Foundayo approvals (T2D) and international launches ahead, as well as continued strong performance from Mounjaro exUS, we believe Lilly is poised for multi-year growth. We reiterate our Buy rating and $1,281 [price target],"according to a Thursday note.

Within this context, the research firm updated its model, increasing its revenue estimates for full-year 2026 to 2028 to $84.6 billion, $97 billion, and $108.6 billion, respectively, from $83 billion, $94.7 billion and $105 billion. Analysts also lifted their EPS assumptions for the same three-year period.

According to Truist, the company's anticipated catalysts for the rest of 2026 include key regulatory decisions for tirzepatide in cardiovascular outcomes, orforglipron for type 2 diabetes, and pirtobrutinib as a first-line treatment for chronic lymphocytic leukemia, among others.